LIFR-AS1 Modulates Sufu to Inhibit Cell Proliferation and Migration by MiR-197-3p in Breast Cancer

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2019 May 26

PMID 31127025

Citations 24

Authors

Fangfang Xu

Hui Li

ChengJiu Hu

Affiliations

Soon will be listed here.

Abstract

Numerous evidence has recently demonstrated that long non-coding RNAs (lncRNAs) play vital roles in the oncogenesis and development of a wide range of human neoplasms. Leukemia inhibitory factor receptor antisense RNA 1 (LIFR-AS1), a novel cancer-related lncRNA, has been reported to be under-expressed in breast cancer and associated with poor prognosis. However, the exact role of LIFR-AS1 in breast cancer remains largely unclear. The present study aimed to investigate the biological role of LIFR-AS1 in breast cancer and clarify the potential molecular mechanisms. In the present study, we found that LIFR-AS1 was significantly down-regulated in both tissues and cell lines. Furthermore, over-expression of LIFR-AS1 inhibited breast cancer cell proliferation, colony formation, migration and invasion, whereas knockdown of LIFR-AS1 promoted breast cancer cell proliferation, colony formation, migration and invasion. Moreover, LIFR-AS1 was observed to up-regulate suppressor of fused gene () expression by competitively binding to miR-197-3p in breast cancer cells. Notably, miR-197-3p inhibitor reversed the promoting effects of LIFR-AS1 knockdown on breast cancer cell proliferation, colony formation, migration and invasion. Additionally, LIFR-AS1 knockdown promoted tumor growth To sum up, our results imply the tumor-suppressing role of LIFR-AS1 in breast cancer.

Citing Articles

Upregulation of Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases.

Draskovic T, Rankovic B, Zidar N, Hauptman N Genes (Basel). 2025; 15(12.

PMID: 39766812 PMC: 11675665. DOI: 10.3390/genes15121545.

Hedgehog pathway and cancer: A new area (Review).

Shen D, Xia Y, Fu Y, Cao Q, Chen W, Zhu Y Oncol Rep. 2024; 52(3).

PMID: 38994763 PMC: 11267502. DOI: 10.3892/or.2024.8775.

Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancer.

Kokot A, Gadakh S, Saha I, Gajda E, Lazniewski M, Rakshit S Curr Issues Mol Biol. 2024; 46(3):2713-2740.

PMID: 38534787 PMC: 10969458. DOI: 10.3390/cimb46030171.

Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies.

Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y Signal Transduct Target Ther. 2023; 8(1):315.

PMID: 37596267 PMC: 10439210. DOI: 10.1038/s41392-023-01559-5.

Genome-wide screening for differentially methylated long noncoding RNAs identifies LIFR-AS1 as an epigenetically regulated lncRNA that inhibits the progression of colorectal cancer.

Song P, Li Y, Wang F, Pu L, Bao L, Gao H Clin Epigenetics. 2022; 14(1):138.

PMID: 36316703 PMC: 9624034. DOI: 10.1186/s13148-022-01361-0.

References

Paces-Fessy M, Boucher D, Petit E, Paute-Briand S, Blanchet-Tournier M . The negative regulator of Gli, Suppressor of fused (Sufu), interacts with SAP18, Galectin3 and other nuclear proteins. Biochem J. 2003; 378(Pt 2):353-62. PMC: 1223961. DOI: 10.1042/BJ20030786. View

Hussain S, Palmer D, Stevens A, Spooner D, Poole C, Rea D . Role of chemotherapy in breast cancer. Expert Rev Anticancer Ther. 2005; 5(6):1095-110. DOI: 10.1586/14737140.5.6.1095. View

Lee Y, Kawagoe R, Sasai K, Li Y, Russell H, Curran T . Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene. 2007; 26(44):6442-7. DOI: 10.1038/sj.onc.1210467. View

Kasai K, Inaguma S, Yoneyama A, Yoshikawa K, Ikeda H . SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cell. Cancer Res. 2008; 68(19):7723-9. DOI: 10.1158/0008-5472.CAN-07-6661. View

Okamura Y, Nomoto S, Kanda M, Li Q, Nishikawa Y, Sugimoto H . Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett. 2009; 289(2):170-7. DOI: 10.1016/j.canlet.2009.08.013. View

Chen J, Lu L, Feng Y, Wang H, Dai L, Li Y . PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett. 2010; 300(1):48-56. DOI: 10.1016/j.canlet.2010.09.005. View

Shi T, Mazumdar T, DeVecchio J, Duan Z, Agyeman A, Aziz M . cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PLoS One. 2010; 5(10). PMC: 2948497. DOI: 10.1371/journal.pone.0013054. View

Belaid A, Kanoun S, Kallel A, Ghorbel I, Azoury F, Heymann S . [Breast cancer with axillary lymph node involvement]. Cancer Radiother. 2010; 14 Suppl 1:S136-46. DOI: 10.1016/S1278-3218(10)70017-2. View

Santos R, Teixeira A, Mayorano M, Carrara H, Andrade J, Takahashi C . DNA repair genes XRCC1 and XRCC3 polymorphisms and their relationship with the level of micronuclei in breast cancer patients. Genet Mol Biol. 2011; 33(4):637-40. PMC: 3036161. DOI: 10.1590/S1415-47572010005000082. View

10.

Augoff K, McCue B, Plow E, Sossey-Alaoui K . miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer. 2012; 11:5. PMC: 3298503. DOI: 10.1186/1476-4598-11-5. View

11.

Migliaccio A, Castoria G, de Falco A, Bilancio A, Giovannelli P, Di Donato M . Polyproline and Tat transduction peptides in the study of the rapid actions of steroid receptors. Steroids. 2012; 77(10):974-8. DOI: 10.1016/j.steroids.2012.01.014. View

12.

Hinohara K, Kobayashi S, Kanauchi H, Shimizu S, Nishioka K, Tsuji E . ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A. 2012; 109(17):6584-9. PMC: 3340023. DOI: 10.1073/pnas.1113271109. View

13.

Hamada S, Satoh K, Miura S, Hirota M, Kanno A, Masamune A . miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol. 2012; 228(6):1255-63. DOI: 10.1002/jcp.24280. View

14.

Justo N, Wilking N, Jonsson B, Luciani S, Cazap E . A review of breast cancer care and outcomes in Latin America. Oncologist. 2013; 18(3):248-56. PMC: 3607519. DOI: 10.1634/theoncologist.2012-0373. View

15.

Gusev Y, Riggins R, Bhuvaneshwar K, Gauba R, Sheahan L, Clarke R . In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. Cancer Inform. 2013; 12:31-51. PMC: 3579429. DOI: 10.4137/CIN.S10329. View

16.

Tariki M, Wieczorek S, Schneider P, Banfer S, Veitinger S, Jacob R . RIO kinase 3 acts as a SUFU-dependent positive regulator of Hedgehog signaling. Cell Signal. 2013; 25(12):2668-75. DOI: 10.1016/j.cellsig.2013.08.037. View

17.

Wei P, Han B, Chen Y . Role of long non-coding RNAs in normal and malignant hematopoiesis. Sci China Life Sci. 2013; 56(10):867-75. DOI: 10.1007/s11427-013-4550-9. View

18.

Li H, Yu B, Li J, Su L, Yan M, Zhu Z . Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014; 5(8):2318-29. PMC: 4039165. DOI: 10.18632/oncotarget.1913. View

19.

Yang G, Lu X, Yuan L . LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014; 1839(11):1097-109. DOI: 10.1016/j.bbagrm.2014.08.012. View

20.

Bilancio A, Migliaccio A . Phosphoinositide 3-kinase assay in breast cancer cell extracts. Methods Mol Biol. 2014; 1204:145-53. DOI: 10.1007/978-1-4939-1346-6_13. View